FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4307129319> ?p ?o ?g. }

• W4307129319 abstract "Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Most of the infected individuals have recovered without complications, but a few patients develop multiple organ involvements. Previous reports suggest an association between COVID-19 and various inflammatory myopathies, in addition to autoimmune diseases. COVID-19 has been known to exacerbate preexisting autoimmune diseases and trigger various autoantibodies and autoimmune disease occurrence. Here we report a case of complicated COVID-19 with anti-synthetase autoantibodies (ASSs) presenting with skin rash, muscle weakness, and interstitial lung disease (ILD) and subsequently diagnosed with dermatomyositis (DM). A 47-year-old Japanese male patient without any previous history of illness, including autoimmune diseases, presented with a high fever, sore throat, and cough. Oropharyngeal swab for SARS-Cov-2 polymerase chain reaction tested positive. He was isolated at home and did not require hospitalization. However, his respiratory symptoms continued, and he was treated with prednisolone (20 mg/day) for 14 days due to the newly developing interstitial shadows over the lower lobes of both lungs. These pulmonary manifestations remitted within a week. He presented with face edema and myalgia 4 weeks later when he was off corticosteroids. Subsequently, he presented with face erythema, V-neck skin rash, low-grade fever, and exertional dyspnea. High-resolution computed tomography of the chest showed ILD. Biochemical analysis revealed creatine kinase and aldolase elevations, in addition to transaminases. Anti-aminoacyl tRNA synthetase (ARS) was detected using an enzyme-linked immunosorbent assay (170.9 U/mL) (MESACUP™ (Medical &amp; Biological Laboratories, Japan), and the tRNA component was identified as anti-PL-7 and anti-Ro-52 antibodies using an immunoblot assay [EUROLINE Myositis Antigens Profile 3 (IgG), Euroimmun, Lübeck,Germany]. The patient was diagnosed with DM, especially anti- synthase antibody syndrome based on the presence of myositis-specific antibodies, clinical features, and pathological findings. The present case suggests that COVID-19 may have contributed to the production of anti-synthetase antibodies (ASAs) and the development of de novo DM. Our case highlights the importance of the assessment of patients who present with inflammatory myopathy post-COVID-19 and appropriate diagnostic work-up, including ASAs, against the clinical features that mimic DM after post-COVID-19." @default.
• W4307129319 created "2022-10-28" @default.
• W4307129319 creator A5013596644 @default.
• W4307129319 creator A5031416330 @default.
• W4307129319 creator A5036475624 @default.
• W4307129319 creator A5038413661 @default.
• W4307129319 creator A5043136451 @default.
• W4307129319 creator A5044267497 @default.
• W4307129319 creator A5054915048 @default.
• W4307129319 creator A5057574490 @default.
• W4307129319 creator A5059480693 @default.
• W4307129319 creator A5059561328 @default.
• W4307129319 creator A5079822291 @default.
• W4307129319 creator A5088939006 @default.
• W4307129319 date "2022-10-24" @default.
• W4307129319 modified "2023-10-09" @default.
• W4307129319 title "New-onset dermatomyositis following COVID-19: A case report" @default.
• W4307129319 cites W2004009723 @default.
• W4307129319 cites W2019355614 @default.
• W4307129319 cites W2109091387 @default.
• W4307129319 cites W2141262625 @default.
• W4307129319 cites W2163773162 @default.
• W4307129319 cites W2762816177 @default.
• W4307129319 cites W2790466592 @default.
• W4307129319 cites W2965421338 @default.
• W4307129319 cites W3001118548 @default.
• W4307129319 cites W3006643024 @default.
• W4307129319 cites W3016393661 @default.
• W4307129319 cites W3020853685 @default.
• W4307129319 cites W3034241962 @default.
• W4307129319 cites W3037676127 @default.
• W4307129319 cites W3039048819 @default.
• W4307129319 cites W3041319886 @default.
• W4307129319 cites W3107638866 @default.
• W4307129319 cites W3111853361 @default.
• W4307129319 cites W3114478940 @default.
• W4307129319 cites W3118973178 @default.
• W4307129319 cites W3126934625 @default.
• W4307129319 cites W3130206057 @default.
• W4307129319 cites W3132728920 @default.
• W4307129319 cites W3136525657 @default.
• W4307129319 cites W3137461703 @default.
• W4307129319 cites W3150658413 @default.
• W4307129319 cites W3160449499 @default.
• W4307129319 cites W3162905796 @default.
• W4307129319 cites W3167578500 @default.
• W4307129319 cites W3177181682 @default.
• W4307129319 cites W3185014427 @default.
• W4307129319 cites W3187827015 @default.
• W4307129319 cites W3196963771 @default.
• W4307129319 cites W3198936050 @default.
• W4307129319 cites W3216011784 @default.
• W4307129319 cites W4200255055 @default.
• W4307129319 cites W4200510971 @default.
• W4307129319 cites W4206127129 @default.
• W4307129319 cites W4225328546 @default.
• W4307129319 cites W4248767946 @default.
• W4307129319 doi "https://doi.org/10.3389/fimmu.2022.1002329" @default.
• W4307129319 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36353621" @default.
• W4307129319 hasPublicationYear "2022" @default.
• W4307129319 type Work @default.
• W4307129319 citedByCount "8" @default.
• W4307129319 countsByYear W43071293192022 @default.
• W4307129319 countsByYear W43071293192023 @default.
• W4307129319 crossrefType "journal-article" @default.
• W4307129319 hasAuthorship W4307129319A5013596644 @default.
• W4307129319 hasAuthorship W4307129319A5031416330 @default.
• W4307129319 hasAuthorship W4307129319A5036475624 @default.
• W4307129319 hasAuthorship W4307129319A5038413661 @default.
• W4307129319 hasAuthorship W4307129319A5043136451 @default.
• W4307129319 hasAuthorship W4307129319A5044267497 @default.
• W4307129319 hasAuthorship W4307129319A5054915048 @default.
• W4307129319 hasAuthorship W4307129319A5057574490 @default.
• W4307129319 hasAuthorship W4307129319A5059480693 @default.
• W4307129319 hasAuthorship W4307129319A5059561328 @default.
• W4307129319 hasAuthorship W4307129319A5079822291 @default.
• W4307129319 hasAuthorship W4307129319A5088939006 @default.
• W4307129319 hasBestOaLocation W43071293191 @default.
• W4307129319 hasConcept C126322002 @default.
• W4307129319 hasConcept C16005928 @default.
• W4307129319 hasConcept C203014093 @default.
• W4307129319 hasConcept C2776715498 @default.
• W4307129319 hasConcept C2777543607 @default.
• W4307129319 hasConcept C2777714996 @default.
• W4307129319 hasConcept C2777870961 @default.
• W4307129319 hasConcept C2778552304 @default.
• W4307129319 hasConcept C2778570526 @default.
• W4307129319 hasConcept C2778616394 @default.
• W4307129319 hasConcept C2778751314 @default.
• W4307129319 hasConcept C71924100 @default.
• W4307129319 hasConcept C90924648 @default.
• W4307129319 hasConceptScore W4307129319C126322002 @default.
• W4307129319 hasConceptScore W4307129319C16005928 @default.
• W4307129319 hasConceptScore W4307129319C203014093 @default.
• W4307129319 hasConceptScore W4307129319C2776715498 @default.
• W4307129319 hasConceptScore W4307129319C2777543607 @default.
• W4307129319 hasConceptScore W4307129319C2777714996 @default.
• W4307129319 hasConceptScore W4307129319C2777870961 @default.
• W4307129319 hasConceptScore W4307129319C2778552304 @default.
• W4307129319 hasConceptScore W4307129319C2778570526 @default.

• next